| Status | Suspended |
| Process | STA pre-2018 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Lyndsey Unwin |
| Project manager: | |
| Technical Lead: | Helen Tucker |
Consultees
| Manufacturers/sponsors | Teva Pharmaceuticals (laquinimod) |
| Others | Department of Health |
| NHS Brent CCG | |
| NHS England | |
| NHS South Lincolnshire CCG | |
| Welsh Government | |
| Patient/carer groups | Afiya Trust |
| Black Health Agency | |
| Brain and Spine Foundation | |
| Disability Rights UK | |
| Equalities National Council | |
| Leonard Cheshire Disability | |
| Multiple Sclerosis National Therapy Centres | |
| Multiple Sclerosis Resource Centre | |
| Multiple Sclerosis Society | |
| Multiple Sclerosis Trust | |
| Muslim Council of Britain | |
| Muslim Health Network | |
| Neurological Alliance | |
| Neurosupport | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Sue Ryder | |
| Professional groups | Association of British Neurologists |
| British Geriatrics Society | |
| British Neuropathological Society | |
| British Society of Rehabilitative Medicine | |
| Chartered Society of Physiotherapy | |
| College of Occupational Therapist | |
| Institute of Neurology | |
| Primary Care Neurology Society | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Therapists in MS (TIMS) | |
| United Kingdom Clinical Pharmacy Association | |
| United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA) |
Commentators
| Associated Public Health Groups | tbc |
| Evidence Review Group | Kleijnen Systematic Reviews |
| National Institute for Health Research Health Technology Assessment Programme | |
| Associated Guideline Groups | |
| National Clinical Guideline Centre | |
| General | Allied Health Professionals Federation |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Commissioning Support Appraisals Service | |
| Department of Health,Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Health Research Authority | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Commercial Medicines Unit | |
| NHS Confederation | |
| Public Health Wales NHS Trust | |
| Scottish Medicines Consortium | |
| Wales Neurological Alliance | |
| Possible comparator manufacturer(s) | Bayer (interferon beta-1b) |
| Biogen Idec (interferon beta-1a, natalizumab, dimethyl fumarate) | |
| Elan Pharma International (natalizumab) | |
| Genzyme (teriflunomide, alemtuzumab) | |
| Merck Serono (interferon beta-1a) | |
| Novartis Pharmaceuticals UK (fingolimod, interferon beta-1b) | |
| Teva Pharmaceuticals (glatiramer actetate) | |
| Relevant research groups | Brain Research Trust |
| Cochrane Multiple Sclerosis Group | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research | |
| Research Institute for the Care of Older People |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 July 2014 | We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve laquinimod for the treatment of relapsing-remitting multiple sclerosis. |
| 20 May 2014 | Following the opinion recently issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) we are rescheduling this appraisal. NICE cannot issue consultation documents or guidance on a technology until UK regulatory approval has been granted. We will therefore need to reschedule the appraisal to align with the latest regulatory expectations. |
| 03 January 2014 | A further draft scope consultation took place in October 2013 |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance